{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:09:07Z","timestamp":1778890147928,"version":"3.51.4"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T00:00:00Z","timestamp":1688256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001316","name":"Solvay Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["SP\/14\/3\/31114"],"award-info":[{"award-number":["SP\/14\/3\/31114"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["SP\/03\/002"],"award-info":[{"award-number":["SP\/03\/002"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["SP\/08\/010\/25939"],"award-info":[{"award-number":["SP\/08\/010\/25939"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["PG\/05\/013\/18296"],"award-info":[{"award-number":["PG\/05\/013\/18296"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011718","name":"Macular Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00017\/5"],"award-info":[{"award-number":["MC_UU_00017\/5"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00017\/3"],"award-info":[{"award-number":["MC_UU_00017\/3"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.conctc.2023.101184","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T21:26:08Z","timestamp":1688505968000},"page":"101184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8647-0366","authenticated-orcid":false,"given":"Emily","family":"Sammons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5909-4265","authenticated-orcid":false,"given":"Georgina","family":"Buck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Wallendszus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imen","family":"Hammami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Parish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane","family":"Armitage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2023.101184_bib1","series-title":"World Report on Vision","year":"2019"},{"key":"10.1016\/j.conctc.2023.101184_bib2","article-title":"The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy","volume":"7","author":"Zhao","year":"2018","journal-title":"Drugs Context (US)"},{"issue":"14","key":"10.1016\/j.conctc.2023.101184_bib3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.conctc.2023.101184_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/diab.9.1.9","article-title":"Retinal capillary microaneurysms: a concept of pathogenesis","volume":"9","author":"Pope","year":"1960","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.conctc.2023.101184_bib5","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.2337\/diabetes.50.6.1432","article-title":"Increased prevalence of microthromboses in retinal capillaries of diabetic individuals","volume":"50","author":"Boeri","year":"2001","journal-title":"Diabetes"},{"issue":"7349","key":"10.1016\/j.conctc.2023.101184_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0140-6736(64)90008-X","article-title":"Diabetic retinopathy and rheumatoid arthritis","volume":"2","author":"Powell","year":"1964","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.conctc.2023.101184_bib7","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.2337\/diabetes.54.12.3418","article-title":"Aspirin at low-intermediate concentrations protects retinal vessels in experimental diabetic retinopathy through non\u2013platelet-mediated effects","volume":"54","author":"Sun","year":"2005","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.conctc.2023.101184_bib8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.exer.2008.10.008","article-title":"Attenuation of diabetes-induced retinal vasoconstriction by a thromboxane receptor antagonist","volume":"88","author":"Wright","year":"2009","journal-title":"Exp. Eye Res."},{"issue":"7","key":"10.1016\/j.conctc.2023.101184_bib9","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2337\/diabetes.50.7.1636","article-title":"Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin","volume":"50","author":"Kern","year":"2001","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.conctc.2023.101184_bib10","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1167\/iovs.08-3328","article-title":"Protective effects of a coumarin derivative in diabetic rats","volume":"50","author":"Bucolo","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.conctc.2023.101184_bib11","first-page":"438","article-title":"Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression","volume":"16","author":"Joussen","year":"2002","journal-title":"FASEB (Fed. Am. Soc. Exp. Biol.) J."},{"issue":"3","key":"10.1016\/j.conctc.2023.101184_bib12","first-page":"153","article-title":"Aspirin and prostacyclin treatment of diabetic dogs","volume":"7","author":"Waitzman","year":"1983","journal-title":"Metab. Pediatr. Syst. Ophthalmol."},{"key":"10.1016\/j.conctc.2023.101184_bib13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0161-6420(13)38010-5","article-title":"Effects of aspirin treatment on diabetic retinopathy. ETDRS Report Number 8","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"issue":"5 Suppl","key":"10.1016\/j.conctc.2023.101184_bib14","first-page":"741","article-title":"Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.conctc.2023.101184_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2337\/diab.38.4.491","article-title":"Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial","volume":"38","year":"1989","journal-title":"Diabetes"},{"issue":"9678","key":"10.1016\/j.conctc.2023.101184_bib16","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.conctc.2023.101184_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.preteyeres.2004.06.002","article-title":"The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina","volume":"24","author":"SanGiovanni","year":"2005","journal-title":"Prog. Retin. Eye Res."},{"issue":"3","key":"10.1016\/j.conctc.2023.101184_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000329470","article-title":"Alpha-lipoic acid for the prevention of diabetic macular edema","volume":"226","author":"Haritoglou","year":"2011","journal-title":"Ophthalmologica"},{"issue":"3","key":"10.1016\/j.conctc.2023.101184_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamacardio.2017.5205","article-title":"Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals","volume":"3","author":"Aung","year":"2018","journal-title":"JAMA Cardiology"},{"issue":"2","key":"10.1016\/j.conctc.2023.101184_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1076\/opep.6.2.125.1558","article-title":"Do age-related macular degeneration and cardiovascular disease share common antecedents?","volume":"6","author":"Snow","year":"1999","journal-title":"Ophthalmic Epidemiol."},{"issue":"6","key":"10.1016\/j.conctc.2023.101184_bib21","first-page":"687","article-title":"Aspirin and age-related macular degeneration: positives versus negatives","volume":"13","author":"Nowak","year":"2014","journal-title":"Expet Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.conctc.2023.101184_bib22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1517\/14740338.2014.889680","article-title":"Does long-term aspirin use increase the risk of neovascular age-related macular degeneration?","volume":"13","author":"Christen","year":"2014","journal-title":"Expet Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.conctc.2023.101184_bib23","first-page":"691","article-title":"Does aspirin increase the risk of age-related macular degeneration?","volume":"13","author":"Chong","year":"2014","journal-title":"Expet Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.conctc.2023.101184_bib24","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/archopht.123.6.774","article-title":"Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers","volume":"123","author":"Seddon","year":"2005","journal-title":"Arch. Ophthalmol."},{"issue":"3","key":"10.1016\/j.conctc.2023.101184_bib25","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9394(02)01624-0","article-title":"A role for local inflammation in the formation of drusen in the aging eye","volume":"134","author":"Anderson","year":"2002","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.conctc.2023.101184_bib26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.preteyeres.2009.11.003","article-title":"The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited","volume":"29","author":"Anderson","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"issue":"6","key":"10.1016\/j.conctc.2023.101184_bib27","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.178.6.3831","article-title":"Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein","volume":"178","author":"Laine","year":"2007","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.conctc.2023.101184_bib28","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.ophtha.2009.05.031","article-title":"Low-dose aspirin and medical record confirmed age-related macular degeneration in a randomized trial of women","volume":"116","author":"Christen","year":"2009","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.conctc.2023.101184_bib29","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.ophtha.2010.02.003","article-title":"C-reactive protein levels and complement factor H polymorphism interaction in age-related macular degeneration and its progression","volume":"117","author":"Robman","year":"2010","journal-title":"Ophthalmology"},{"issue":"23","key":"10.1016\/j.conctc.2023.101184_bib30","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/jama.2012.65406","article-title":"Long term use of aspirin and age-related macular degeneration","volume":"308","author":"Klein","year":"2012","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.conctc.2023.101184_bib31","series-title":"Age-Related Maculopathy in a Randomized Trial of Low-Dose Aspirin Among US Physicians Archives of Ophthalmology","first-page":"1143","volume":"vol. 119","author":"Christen","year":"2001"},{"key":"10.1016\/j.conctc.2023.101184_bib32","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.conctc.2017.03.005","article-title":"Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: rationale and study design of the ASPREE-AMD study","volume":"6","author":"Robman","year":"2017","journal-title":"Contemporary Clin. Trials Commun."},{"key":"10.1016\/j.conctc.2023.101184_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2020.100667","article-title":"Baseline characteristics and age-related macular degeneration in participants of the \"ASPirin in Reducing Events in the Elderly\" (ASPREE)-AMD trial","volume":"20","author":"Robman","year":"2020","journal-title":"Contemporary Clin. Trials Commun."},{"issue":"8","key":"10.1016\/j.conctc.2023.101184_bib34","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.ophtha.2013.01.005","article-title":"Oral docosahexaenoic acid in the prevention of exudative age-related macular degeneration: the Nutritional AMD Treatment 2 study","volume":"120","author":"Souied","year":"2013","journal-title":"Ophthalmology"},{"issue":"19","key":"10.1016\/j.conctc.2023.101184_bib35","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.2013.4997","article-title":"Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial","volume":"309","year":"2013","journal-title":"J. Am. Med. Assoc."},{"issue":"12","key":"10.1016\/j.conctc.2023.101184_bib36","first-page":"1280","article-title":"Effect of vitamin D and \u03c9-3 fatty acid supplementation on risk of age-related macular degeneration: an ancillary study of the VITAL randomized clinical trial","volume":"138","author":"Christen","year":"2020","journal-title":"J. Am. Med. Ass. Ophthalmol."},{"key":"10.1016\/j.conctc.2023.101184_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ahj.2017.12.006","article-title":"ASCEND: a Study of Cardiovascular Events iN Diabetes: characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes","volume":"198","author":"Bowman","year":"2018","journal-title":"Am. Heart J."},{"issue":"16","key":"10.1016\/j.conctc.2023.101184_bib38","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.conctc.2023.101184_bib39","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.conctc.2023.101184_bib40","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1186\/s13063-016-1354-9","article-title":"Cost-effective recruitment methods for a large randomised trial in people with diabetes: a Study of Cardiovascular Events iN Diabetes (ASCEND)","volume":"17","author":"Aung","year":"2016","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.conctc.2023.101184_bib41","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"key":"10.1016\/j.conctc.2023.101184_bib42","first-page":"1","volume":"7","year":"2012"},{"issue":"6","key":"10.1016\/j.conctc.2023.101184_bib43","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00592-017-0974-1","article-title":"The English national screening Programme for diabetic retinopathy 2003-2016","volume":"54","author":"Scanlon","year":"2017","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.conctc.2023.101184_bib44","series-title":"NHS Diabetic Eye Screening Programme: Grading Definitions for Referable Disease","year":"2021"},{"key":"10.1016\/j.conctc.2023.101184_bib45","series-title":"NHS Diabetic Eye Screening Programme: Overview of Patient Pathway, Grading Pathway, Surveillance Pathways and Referral Pathways","year":"2017"},{"key":"10.1016\/j.conctc.2023.101184_bib46","series-title":"Validity and Completeness of the NHS Number in Primary and Secondary Care: Electronic Data in England 1991-2013","author":"Hippisley-Cox","year":"2013"},{"issue":"7","key":"10.1016\/j.conctc.2023.101184_bib47","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-list-item national eye Institute visual function questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.conctc.2023.101184_bib48","series-title":"NHS Diabetic Eye Screening Programme: Grading Definitions for Referable Disease","year":"2017"},{"issue":"6","key":"10.1016\/j.conctc.2023.101184_bib49","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/bjc.1976.220","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design","volume":"34","author":"Peto","year":"1976","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.conctc.2023.101184_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples","volume":"35","author":"Peto","year":"1977","journal-title":"Br. J. Cancer"},{"issue":"69","key":"10.1016\/j.conctc.2023.101184_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001571","article-title":"5-lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of \u03c9-3 polyunsaturated fatty acids","volume":"3","author":"Sapieha","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.conctc.2023.101184_bib52","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0033-0620(85)80003-7","article-title":"Beta blockade during and after myocardial infarction: an overview of the randomized trials","volume":"27","author":"Yusuf","year":"1985","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.conctc.2023.101184_bib53","series-title":"Principles and Practice of Clinical Research","first-page":"285","article-title":"Chapter 23 - an introduction to survival analysis","author":"Lee Johnson","year":"2012"},{"issue":"9754","key":"10.1016\/j.conctc.2023.101184_bib54","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"issue":"79","key":"10.1016\/j.conctc.2023.101184_bib55","first-page":"1","article-title":"Trends in the use of complementary health approaches among adults: United States, 2002-2012","author":"Clarke","year":"2015","journal-title":"Natl Health Stat Report"},{"issue":"1","key":"10.1016\/j.conctc.2023.101184_bib56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1114248","article-title":"Estimating glomerular filtration rate from serum creatinine and cystatin C","volume":"367","author":"Inker","year":"2012","journal-title":"N. Engl. J. Med."}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865423001308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865423001308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:31:16Z","timestamp":1778887876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865423001308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":56,"alternative-id":["S2451865423001308"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2023.101184","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2023.101184","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101184"}}